Log in

NASDAQ:APTX - Aptinyx Stock Price, Forecast & News

$3.47
+0.02 (+0.58 %)
(As of 02/17/2020 02:27 AM ET)
Today's Range
$3.41
Now: $3.47
$3.58
50-Day Range
$3.15
MA: $3.83
$5.03
52-Week Range
$2.61
Now: $3.47
$6.00
Volume195,776 shs
Average Volume515,765 shs
Market Capitalization$152.16 million
P/E RatioN/A
Dividend YieldN/A
Beta0.1
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:APTX
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.57 million
Book Value$4.46 per share

Profitability

Net Income$-53,280,000.00
Net Margins-1,523.09%

Miscellaneous

EmployeesN/A
Market Cap$152.16 million
Next Earnings Date3/19/2020 (Estimated)
OptionableNot Optionable

Receive APTX News and Ratings via Email

Sign-up to receive the latest news and ratings for APTX and its competitors with MarketBeat's FREE daily newsletter.


Aptinyx (NASDAQ:APTX) Frequently Asked Questions

What is Aptinyx's stock symbol?

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

How were Aptinyx's earnings last quarter?

Aptinyx Inc (NASDAQ:APTX) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.44) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.44). The business had revenue of $0.94 million for the quarter, compared to analysts' expectations of $0.91 million. Aptinyx had a negative return on equity of 44.24% and a negative net margin of 1,523.09%. View Aptinyx's Earnings History.

When is Aptinyx's next earnings date?

Aptinyx is scheduled to release their next quarterly earnings announcement on Thursday, March 19th 2020. View Earnings Estimates for Aptinyx.

What price target have analysts set for APTX?

6 Wall Street analysts have issued 1-year target prices for Aptinyx's shares. Their forecasts range from $7.00 to $12.00. On average, they expect Aptinyx's share price to reach $10.33 in the next year. This suggests a possible upside of 197.8% from the stock's current price. View Analyst Price Targets for Aptinyx.

What is the consensus analysts' recommendation for Aptinyx?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptinyx.

Has Aptinyx been receiving favorable news coverage?

News articles about APTX stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aptinyx earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Aptinyx.

Are investors shorting Aptinyx?

Aptinyx saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 192,200 shares, an increase of 13.4% from the January 15th total of 169,500 shares. Based on an average daily trading volume, of 240,200 shares, the days-to-cover ratio is currently 0.8 days. Approximately 0.9% of the shares of the company are sold short. View Aptinyx's Current Options Chain.

Who are some of Aptinyx's key competitors?

What other stocks do shareholders of Aptinyx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX), Opko Health (OPK), VBI Vaccines (VBIV), vTv Therapeutics (VTVT), Canopy Growth (CGC), Kadmon (KDMN), Strongbridge Biopharma (SBBP), SCYNEXIS (SCYX), Abeona Therapeutics (ABEO) and ADMA Biologics (ADMA).

Who are Aptinyx's key executives?

Aptinyx's management team includes the folowing people:
  • Dr. Norbert G. Riedel, Pres, CEO & Director (Age 61)
  • Dr. Joseph R. Moskal Ph.D., Chief Scientific Officer (Age 68)
  • Dr. Torsten Meldgaard Madsen, Chief Medical Officer (Age 51)
  • Mr. Ashish Khanna, CFO & Chief Bus. Officer (Age 43)
  • Ms. Betty Y. Jang, VP of Legal Affairs (Age 50)

When did Aptinyx IPO?

(APTX) raised $77 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Who are Aptinyx's major shareholders?

Aptinyx's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Farallon Capital Management LLC (0.93%), Renaissance Technologies LLC (0.70%), Jacobs Levy Equity Management Inc. (0.43%), Oxford Asset Management LLP (0.40%), Marshall Wace LLP (0.33%) and Acadian Asset Management LLC (0.26%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach and Torsten M Madsen. View Institutional Ownership Trends for Aptinyx.

Which major investors are selling Aptinyx stock?

APTX stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Marshall Wace LLP, Oxford Asset Management LLP, Russell Investments Group Ltd., Alambic Investment Management L.P. and Goldman Sachs Group Inc.. View Insider Buying and Selling for Aptinyx.

Which major investors are buying Aptinyx stock?

APTX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Jacobs Levy Equity Management Inc., DCF Advisers LLC, Spark Investment Management LLC and Acadian Asset Management LLC. Company insiders that have bought Aptinyx stock in the last two years include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach and Torsten M Madsen. View Insider Buying and Selling for Aptinyx.

How do I buy shares of Aptinyx?

Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aptinyx's stock price today?

One share of APTX stock can currently be purchased for approximately $3.47.

How big of a company is Aptinyx?

Aptinyx has a market capitalization of $152.16 million and generates $6.57 million in revenue each year. The company earns $-53,280,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. View Additional Information About Aptinyx.


MarketBeat Community Rating for Aptinyx (NASDAQ APTX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  99 (Vote Outperform)
Underperform Votes:  90 (Vote Underperform)
Total Votes:  189
MarketBeat's community ratings are surveys of what our community members think about Aptinyx and other stocks. Vote "Outperform" if you believe APTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel